Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Despain · SciRah

Researcher profile · Semantic Scholar

D. Despain

Share profile

D. Despain — researcher profile on SciRah

h-index: 20
Works: 45
Citations: 4,313

Most-cited papers

Natalizumab induction and maintenance therapy for Crohn's disease.
W. Sandborn, J. Colombel, R. Enns, B. Feagan +11 more
2005New England Journal of Medicine927 citations Open access
Semantic Scholar
Rociletinib in EGFR-mutated non-small-cell lung cancer.
L. Sequist, J. Soria, J. Goldman, H. Wakelee +26 more
2015New England Journal of Medicine628 citations Open access
Semantic Scholar
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
W. Abida, A. Patnaik, D. Campbell, J. Shapiro +23 more
2020Journal of Clinical Oncology579 citations Open access
Semantic Scholar
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
K. Fizazi, J. Piulats, M. Reaume, P. Ostler +24 more
2023New England Journal of Medicine333 citations Open access
Semantic Scholar
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study
W. Abida, D. Campbell, A. Patnaik, J. Shapiro +23 more
2020Clinical Cancer Research320 citations Open access
Semantic Scholar
Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.
R. Oudiz, N. Galie', H. Olschewski, F. Torres +10 more
2009Journal of the American College of Cardiology245 citations Open access
Semantic Scholar
Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.
M. Mcgoon, A. Frost, R. Oudiz, D. Badesch +7 more
2006Chest181 citations
Semantic Scholar
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)
C. Karlovich, J. Goldman, Jong-Mu Sun, E. Mann +21 more
2016Clinical Cancer Research172 citations Open access
Semantic Scholar
ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.
D. Badesch, J. Feldman, A. Keogh, M. Mathier +9 more
2012Cardiovascular Therapeutics111 citations
Semantic Scholar
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study
W. Abida, D. Campbell, A. Patnaik, A. Bryce +26 more
2023European Urology108 citations Open access
Semantic Scholar
Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension.
J. Fritz, C. Blair, R. Oudiz, C. Dufton +4 more
2013Chest108 citations Open access
Semantic Scholar
Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses
W. Abida, D. Campbell, A. Patnaik, B. Sautois +12 more
2019Annals of Oncology86 citations Open access
Semantic Scholar
Cell‐Free DNA Next‐Generation Sequencing Prediction of Response and Resistance to Third‐Generation EGFR Inhibitor
E. Helman, Minh Nguyen, C. Karlovich, D. Despain +7 more
2018Clinical Lung Cancer63 citations Open access
Semantic Scholar
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib
A. Loehr, A. Hussain, A. Patnaik, A. Bryce +17 more
2022European Urology61 citations Open access
Semantic Scholar
Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations.
W. Abida, A. Bryce, N. Vogelzang, R. J. Amato +15 more
2018Annals of Oncology61 citations Open access
Semantic Scholar
Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts).
L. Sequist, J. Goldman, H. Wakelee, D. Camidge +15 more
201554 citations
Semantic Scholar
Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension.
J. Klinger, R. Oudiz, R. Spence, D. Despain +1 more
2011American Journal of Cardiology47 citations
Semantic Scholar
LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC)
B. Monk, A. Oaknin, D. O'Malley, M. Wilson +16 more
2024Annals of Oncology43 citations Open access
Semantic Scholar
Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib.
H. Wakelee, S. Gadgeel, J. Goldman, K. Reckamp +15 more
201633 citations
Semantic Scholar
Response to rucaparib in BRCA-mutant metastatic castration-resistant prostate cancer identified by genomic testing in the TRITON2 study
A. Loehr, A. Patnaik, D. Campbell, J. Shapiro +24 more
2021Clinical Cancer Research22 citations Open access
Semantic Scholar
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study
J. Yang, K. Reckamp, Young-chul Kim, S. Novello +15 more
2020JTO Clinical and Research Reports18 citations Open access
Semantic Scholar
Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy.
A. Bryce, J. Piulats, M. Reaume, P. Ostler +16 more
2023Journal of Clinical Oncology15 citations
Semantic Scholar
3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement
A. Varga, D. Camidge, L. Sequist, H. Wakelee +12 more
201513 citations
Semantic Scholar
A phase I study of oral rucaparib in combination with carboplatin.
L. Molife, P. Roxburgh, R. Wilson, Avinash Gupta +15 more
201313 citations Open access
Semantic Scholar
EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.
J. Goldman, C. Karlovich, L. Sequist, V. Meļņikova +23 more
2018JCO Precision Oncology11 citations
Semantic Scholar
Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC).
J. Goldman, J. Soria, H. Wakelee, D. Camidge +12 more
201611 citations
Semantic Scholar
Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with BRCA1 or BRCA2 (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC).
W. Abida, D. Campbell, A. Patnaik, B. Sautois +12 more
20209 citations
Semantic Scholar
Omeprazole Has No Clinically Relevant Effect on the Pharmacokinetics of Ambrisentan.
B. Harrison, D. Despain, A. Mandagere, Gennyne A. Walker +1 more
2009Asian Test Symposium9 citations
Semantic Scholar
Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2.
W. Abida, A. Bryce, N. Vogelzang, R. Amato +16 more
2019Journal of Clinical Oncology6 citations
Semantic Scholar
MA08.01 A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma
H. Wakelee, V. Meļņikova, C. Karlovich, S. Gadgeel +22 more
20176 citations Open access
Semantic Scholar
Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety.
A. Bryce, R. McDermott, J. Piulats, M. Reaume +16 more
2025Journal of Clinical Oncology5 citations Open access
Semantic Scholar
3104 Rociletinib treatment and outcomes in non-small cell lung cancer (NSCLC) patients with negative central testing for T790M
B. Solomon, H. Wakelee, L. Sequist, S. Gadgeel +8 more
20155 citations
Semantic Scholar
Trial of rucaparib in prostate indications 3 (TRITON3): An international, multicenter, randomized, open-label phase 3 study of rucaparib vs physician’s choice of therapy for patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficienc
C. Ryan, S. Watkins, D. Despain, C. Karlovich +3 more
20173 citations
Semantic Scholar
PS01.66: Biomarker Stratification of Outcomes of Third‐Generation EGFR TKI Therapy in Patients with Previously‐Treated Advanced NSCLC: Topic: Medical Oncology
H. Wakelee, J. Goldman, S. Gadgeel, D. Camidge +16 more
2016Journal of Thoracic Oncology3 citations Open access
Semantic Scholar
659P Rucaparib population pharmacokinetics (PPK) and exposure-response (ER) analyses in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2
S. Chowdhury, A. Patnaik, D. Campbell, J. Shapiro +15 more
20202 citations Open access
Semantic Scholar
3088 Efficacy of rociletinib (co-1686) in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) assessed with a plasma EGFR test
S. Gadgeel, J. Soria, J. Goldman, H. Wakelee +15 more
20152 citations
Semantic Scholar
MP16-07 RUCAPARIB VS DOCETAXEL OR SECOND-GENERATION ANDROGEN RECEPTOR PATHWAY INHIBITOR THERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH BRCA MUTATIONS WITH OR WITHOUT LIVER METASTASES IN TRITON3
David Morris, A. Bryce, J. Piulats, M. Reaume +16 more
2025Journal of Urology1 citations
Semantic Scholar
P2.03-058 Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC)
J. Yang, K. Reckamp, Y. Kim, S. Novello +14 more
20171 citations Open access
Semantic Scholar
Abstract 927: Pretreatment and serial plasma assessments of EGFR mutations in NSCLC patients treated with rociletinib (CO-1686)
J. Goldman, C. Karlovich, E. Mann, L. Rolfe +14 more
20151 citations
Semantic Scholar
SIX-MINUTE WALK DISTANCE AND B-TYPE NATRIURETIC PEPTIDE AS DISCRIMINATORS OF SURVIVAL IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
S. Kawut, D. Despain, B. Coar, C. Dufton
20091 citations
Semantic Scholar
Robustness of homogeneity of variance tests for randomized complete block data
G. Schaalje, D. Despain
19961 citations
Semantic Scholar
Impact of prior treatment setting on the efficacy of rucaparib vs physician’s choice in BRCA -mutated castration-resistant prostate cancer (mCRPC) in TRITON3.
S. Sridhar, K. Fizazi, A. Bryce, Simon Chowdhury +14 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
Association of co-occurring gene alterations and clinical activity of rucaparib in patients with BRCA1 or BRCA2 mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC).
W. Abida, A. Patnaik, D. Campbell, J. Shapiro +16 more
20210 citations
Semantic Scholar
(214) Timing of reduction of postoperative pain intensity and opioid analgesia use with the bupivacaine-collagen matrix (INL-001) after open inguinal hernia repair
D. Leiman, H. Minkowitz, D. Despain, M. Jones +1 more
20170 citations Open access
Semantic Scholar
Title: Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase 1 study of rociletinib (CO-1686)
C. Karlovich, J. Goldman, Jong-Mu Sun, E. Mann +23 more
20150 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

W. Abida×14
Invite
W. Abida — researcher profile on SciRah
A. Bryce×14
Invite
A. Bryce — researcher profile on SciRah
S. Chowdhury×14
Invite
S. Chowdhury — researcher profile on SciRah
D. Camidge×13
Invite
D. Camidge — researcher profile on SciRah

×12

Invite

L. Sequist — researcher profile on SciRah

C. Karlovich×12

Invite

C. Karlovich — researcher profile on SciRah

Invite

B. Sautois — researcher profile on SciRah

Invite

A. Simmons — researcher profile on SciRah

Invite

J. Goldman — researcher profile on SciRah

Invite

H. Wakelee — researcher profile on SciRah

Invite

S. Gadgeel — researcher profile on SciRah

N. Vogelzang×10

Invite

N. Vogelzang — researcher profile on SciRah